Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 164

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

Open access
Canonici, Alexandra, Gijsen, Merel, Mullooly, Maeve, Bennett, Ruth, Bouguern, Noujoude, Pedersen, Kasper, O’Brien, Neil A, Roxanis, Ioannis, Li, Ji-Liang, Bridge, Esther, Finn, Richard, Slamon, Dennis, McGowan, Patricia, Duffy, Michael J., O’Donovan, Norma, Crown, John, Kong, Anthony · 2013 · Oncotarget

Abstract

// Alexandra Canonici 1,* , Merel Gijsen 2,* , Maeve Mullooly 4 , Ruth Bennett 2 , Noujoude Bouguern 2 , Kasper Pedersen 1 , Neil A O’Brien 5 , Ioannis Roxanis 6 , Ji-Liang Li 3 , Esther Bridge 3 , Richard Finn 5 , Dennis Slamon 5 , Patricia McGowan 4 , Michael J. Duffy 4 , Norma O’Donovan 1,* , John Crown 1,4,* and Anthony Kong 2,* 1 National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland; 2 Human Epidermal Growth Factor Group, University of Oxford, UK 3 Growth Factor Group, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, UK; 4 Clinical Research Centre, St. Vincent’s University Hospital, and UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland; 5 Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; 6 Department of Cellular Pathology, Oxford University Hospitals and Oxford Biomedical Research Centre, Oxford, United Kingdom. * These authors contributed equally Correspondence: Anthony Kong, email: // John Crown, email: // Norma O’Donovan, email: // Keywords : breast cancer, HER2/ErbB2, trastuzumab (Herceptin), neratinib, panHER inhibitor Received : July 6, 2013 Accepted : July 24, 2013 Published : July 25, 2013 Abstract Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer cell lines. We further assessed its effects with or without trastuzumab in several sensitive and resistant breast cancer cells as well as a BT474 xenograft model. We confirmed that neratinib was significantly more active in HER2-amplified than HER2 non-amplified cell lines. Neratinib decreased the activation of the 4 HER receptors and inhibited downstream pathways. However, HER3 and Akt were reactivated at 24 hours, which was prevented by the combination of trastuzumab and neratinib. Neratinib also decreased pHER2 and pHER3 in acquired trastuzumab resistant cells. Neratinib in combination with trastuzumab had a greater growth inhibitory effect than either drug alone in 4 HER2 positive cell lines. Furthermore, trastuzumab in combination with neratinib was growth inhibitory in SKBR3 and BT474 cells which had acquired resistance to trastuzumab as well as in a BT474 xenograft model. Innately trastuzumab resistant cell lines showed sensitivity to neratinib, but the combination did not enhance response compared to neratinib alone. Levels of HER2 and phospho-HER2 showed a direct correlation with sensitivity to neratinib. Our data indicate that neratinib is an effective anti-HER2 therapy and counteracted both innate and acquired trastuzumab resistance in HER2 positive breast cancer. Our results suggest that combined treatment with trastuzumab and neratinib is likely to be more effective than either treatment alone for both trastuzumab-sensitive breast cancer as well as HER2-positive tumors with acquired resistance to trastuzumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.1148

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N. A., Roxanis, I., Li, J.-L., Bridge, E., Finn, R., Slamon, D., McGowan, P., Duffy, M. J., O’Donovan, N., Crown, J., & Kong, A.
Venue
Oncotarget
Published
2013-07-25
Volume
4
Issue
10
Pages
1592-1605
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1597931794
Cited by
164
References
6
FWCI
5.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.